|
Actos Lawsuits: A Brief Overview:
|
|
|
Actos is manufactured by Takeda Pharmaceuticals. Actos bladder cancer lawsuits against
Takeda have recently begun, the first lawsuits being filed in August 2011. Thousands
of additional Actos lawsuits are expected to follow as potential cases of bladder
cancer and other serious side effects among Actos patients are investigated.
|
|
Many of the lawsuits allege that Takeda knew or should have known that taking Actos
long-term increases the risk of bladder cancer, and that Takeda is responsible for
the serious side effects the patients suffered as a result of taking Actos. Many
of the Actos lawsuits claim that patients suffered side effects after taking Actos
for an extended period of time.
|
|
|
Actos is among a class of drugs known as thiazolidinediones, used in the treatment
of Type 2 diabetes. Both Actos and Avandia were approved in 1999, and although Avandia
has suffered under claims that it caused serious side effects such as edema, fractures
and heart failures, Actos escaped accusations of harm until very recently. While
Actos was on the FDA’s 2002 list of products which were required to report incidences
of heart failure on the label, its sales continued to skyrocket, netting Takeda
Pharmaceuticals over three billion dollars in 2010 alone.
A 2010 study even gave Actos a boost as it seemed to lend credence to the fact that
Actos was a much safer alternative to Avandia. Other studies disagreed, showing
that Actos, especially when taken for longer than a year or in higher dosages came
with a significantly increased risk of bladder cancer—as much as 40%. Since Takeda’s
Actos patent is set to expire in August of 2012, it is believed the company will
experience a sharp drop in sales, not to mention a significant number of lawsuits
among those who believe Takeda knew of the increased risk of bladder cancer yet
failed to warn those taking the drug.
|
The cases of bladder cancer in those taking Actos continue to pour in. Just this
June medical regulators in Germany and France suspended sales of Actos due to its
potential risk of causing bladder cancer. This study found a 22 percent higher risk
of serious bladder cancer in those taking Actos as compared to those who were not
taking the drug. The bladder cancer risk appeared to be the highest in those who
had received a cumulative dosage of 28,000 mg or more throughout the period of study.
Yet another study which looked at the Adverse Event reports to the FDA between the
years 2004 and 2009 suggested that those who took Actos faced a “disproportionate”
risk of developing bladder cancer. In fact, from a half a million side effect reports,
a full fifth of those involved bladder cancer among those taking Actos.
|
When the artery which supplies blood to the heart muscle becomes blocked, your heart
can no longer receive the oxygen-filled blood it needs. When the heart is unable
to receive that oxygen-rich blood, the heart muscles are damaged which can lead
to death or other health problems such as congestive heart failure. Some of the
studies done on Actos show it definitely has the capacity to cause congestive heart
failure or other cardiovascular diseases as well as to create a significantly increased
risk of bladder cancer, particularly in those taking the drug for longer periods
of time.
|
Many of those who are suffering from congestive heart failure do not suspect they
are experiencing problems with their heart. The earliest symptoms can be shortness
of breath, a chronic cough, or feelings of being unable to get a deep breath. If
you have a history of asthma, COPD or emphysema, the person may believe they are
simply experiencing a worsening of the underlying condition. Those who have no history
of breathing difficulties may believe they have the flu or a case of bronchitis.
Those who are suffering from congestive heart failure may be unable to tolerate
even the mildest physical exertion and may feel chronically fatigued. Should congestive
heart failure worsen, fluid can accumulate in the lungs, interfering with the ability
of oxygen to get into the blood. Fluid retention and swelling of the extremities
may be noted, particularly in the evening or after sitting or standing for a prolonged
period of time.
|
Actos is not recommended for use by anyone who has a history of cardiovascular problems
or edema, and can cause significant fluid retention in diabetes patients, especially
when used in conjunction with insulin. Any person who has had symptoms of heart
failure, including a rapid weight gain, fluid buildup or shortness of breath should
talk with their physician before taking Actos. If Actos has been a part of your
diabetes treatment and you have developed congestive heart failure, time is definitely
of the essence. Of course you should first take care of your health, then you should
seek out a qualified attorney who is cognizant of the risks and facts surrounding
the use of Actos.
|
The manufacturers of Avandia, Glaxo-Smith Kline, have already set aside over 400
million dollars for settlements due to harm caused patients who used the drug and
that figure will likely increase as the suits continue to be filed. Actos, a product
of a Japanese corporation, Takeda Pharmaceuticals, was believed to be the safer
alternative to Avandia. In 2008, Actos was the tenth best-selling drug in the United
States with sales of over 2.4 billion dollars, and by 2010 that figure was well
over 3 billion dollars. Unfortunately, the summer of 2011 brought results from several
research studies done on Actos which show that it is possibly as damaging as Avandia,
though perhaps in different ways.
|
Actos was released in 1999 as a drug which increased the body’s sensitivity to insulin,
rapidly rising in popularity over the past twelve years. It is estimated that the
sales of Actos alone garnered Takeda as much as $4.3 billion in 2010, making it
one of the ten best-selling drugs in the United States. Prior to the release of
Actos, studies were done on animals which showed a direct correlation between Actos
and the formation of tumors. Disregarding these results, Takeda forged ahead with
the release of Actos. Takeda took the initiative to conduct a decade-long study
regarding the safety of Actos, and the mid-point results showed that while overall
there appeared to be no increase in the risks for bladder cancer, for those taking
the drug for longer periods of time than twelve months or in high dosages, the risks
could increase by as much as 40%.
|
As a result of the identification of the risks of bladder cancer, French drug regulators
recalled Actos while Germany mandated that Actos not be prescribed to new patients.
New Zealand is in the process of a recall, however the FDA has taken a more relaxed
“wait and see” attitude, stating they will not recall the drug until the results
of further studies are in. Recent months have seen dozens of individuals all across
the United States filing lawsuits regarding the bladder cancer risk associated with
the use of Actos. Results of one study states that 22, 512 patients who have taken
Actos have reported side effects and that .22% of those subsequently developed bladder
cancer.
|
Although Actos has not yet been recalled in the United States, it is not necessary
that it be recalled in order for those damaged by the drug to file a lawsuit for
injuries suffered. Legal action is the most expedient way to recover compensation,
not only for your medical expenses, but for your pain and suffering as well. When
your doctor prescribes a drug for a medical condition, you should not have to wonder
if it has been properly studied prior to being released to the public. It is believed
that Takeda Pharmaceuticals was well aware of the potential ill-effects of the drug
prior to its release, as animal studies resulted in tumors developing in the rats
treated with Actos.
|
The first wave of what many believe to be the tip of the iceberg in Actos lawsuits
was filed in August, 2011. A fifty-four year old woman who took Actos for over a
decade was diagnosed with bladder cancer in 2009. Nancy Rios may end up having her
bladder removed and undergoing chemotherapy and perhaps radiation as well.
In Los Angeles two cases were filed against the manufacturers of Actos, both alleging
that they not only developed serious bladder cancer as a side effect of taking the
drug but also that Takeda knew the risks involved and did not warn them of those
risks. Both residents of Los Angeles County, Roger Pike and Stanley Cook took Actos
for several years. Their complaints include the fact that due in part to scientific
studies done on animals Takeda was well aware of the increased risk of bladder cancer
among humans taking the drug.
The complaints accuse Takeda of neglecting to conduct complete and proper testing
of side effects before releasing it, and assert that several years following the
approval of Actos clinical evidence surfaced which showed a definitive link between
bladder cancer and Actos use and this evidence was willfully concealed from patients
and doctors who prescribed Actos. Both Cook and Pike are seeking general, special,
exemplary and punitive damages as well as compensation for injuries, pain, suffering,
mental anguish and diminished enjoyment of life. Pike also seeks compensatory amounts
for his wife claiming she was bereft of love, comfort, attention and loss of services
and support from her husband.
Plaintiff Betty Thomas is filing suit on behalf of her mother, Maude Kinard, also
in Los Angeles County, alleging her mother developed bladder cancer as a direct
result of taking Actos as a treatment of her Type 2 diabetes. The bladder cancer
eventually led to Maude Kinard’s death, therefore Thomas is alleging that Actos
is not only designed defectively but also that manufacturer Takeda Pharmaceuticals
was negligent in its marketing and sales of Actos, knowing full well of the increased
risks of bladder cancer among those taking the drug. This particular lawsuit accuses
Takeda of underplaying the seriousness of the health risks and offering only vague
or inadequate warnings. Maude Kinard took Actos for six years, developing bladder
cancer in 2006 which precipitated her death in 2008.
Paul McMahan of Minnesota claims Actos caused his bladder cancer and further states
that both Takeda and Eli Lilly and Company were well-aware of the risks of bladder
cancer from the time the drug was approved in 1999. In spite of the fact that Actos
was shown to cause tumors in male rats that were given the drug, it was approved,
and marketed with no warnings regarding bladder cancer risk. It was not until September
of 2010 that the FDA finally issued a safety warning regarding the connection between
Actos and bladder cancer.
|
A class action lawsuit aggregates many individual lawsuits into one lawsuit where
the claimants have an injury in common, with a single representative member of the
class representing the whole. Class actions offer the advantages of greater efficiency
in trying the case and can lower litigation costs, although in some cases class
action settlements can result in lower recoveries for individual class members and
higher attorney fees.
Actos lawsuits are currently being represented on an individual basis by law firms.
No Actos class action lawsuits have yet been filed. The injuries suffered by each
Actos patient from bladder cancer and other complications will be different for
each patient, so that it is not likely that a large number of claims will be similar
enough to be successfully aggregated into a single class representative.
|
Later this year the United States Judicial Panel on Multidistrict Litigation is
expected to decide whether the Actos litigation, which currently includes more than
50 individual lawsuits, should be centralized before one judge. If the cases were
to be consolidated they would be handled similarly to a class action suit during
pretrial litigation and discovery, however if no resolution were reached, each bladder
cancer lawsuit would be handled individually during trial. Actos was taken by millions
of people over the past twelve years, resulting in a potential class action suit
which could include hundreds—or even millions—of injured plaintiffs.
|
Hundreds of patients who took Actos and were diagnosed with bladder cancer are expected
to contact a highly experienced law firm regarding Actos exposure within the next
year. Sullo & Sullo, LLP understands the trauma of developing a disease after taking
a drug they believed to be safe. While the laws regarding defective drugs are quite
complex, our legal team is up to the challenge and would like the opportunity to
evaluate your specific case in order to determine whether or not you have a solid
case against the manufacturers of Actos. Treating bladder cancer, if it is treatable,
can result in huge medical expenses, time lost from work and even a diminished quality
of life. If you took Actos for longer than twelve months and have been diagnosed
with bladder cancer, you may be eligible to file an Actos lawsuit, so call our firm
today for a consultation.
|
|
|
|
Sullo & Sullo, LLP has an experienced team of attorneys who can help you to investigate
your rights and your lawsuit options.
|
|
|
|
To tell us
about your case, please fill out the 'Free Consultation' form in the right pane.
|
|
|
|
|
|
|
|
|
Free Consultation
|
|
Receive an immediate response to your request.
|
|
|
|
|
|
|
Recent Articles and Publications
|
|
|
|
April 25, 2012
|
|
Recovering From Actos-Related Bladder Cancer: Part 1of 2: How Can I Prevent a Recurrence?
|
|
Actos, or pioglitazone, is a prescription medicine used in the treatment of Type-2 diabetes and works by sensitizing cells to the pancreas-produced hormone known as insulin. Insulin is used by the body to regulate the amount of sugar or glucose in the body therefore when cells are more sensitive to insulin, sugar in the blood naturally moves more easily into cells.
|
|
Full Story
|
|
|
|
|
April 23, 2012
|
|
Recovering From Actos-Related Bladder Cancer: Part 2 of 2: What All Actos Users Should Know:
|
|
Actos, a drug used in the treatment of Type 2 Diabetes has been shown to carry a risk of bladder cancer, particularly among those who are elderly or who have taken the drug in higher doses or for extended periods of time (longer than one year). Although the drug has not yet been recalled by the FDA, it has fallen under intense scrutiny and has been pulled from the French and German markets.
|
|
Full Story
|
|
|
|
|
March 03, 2012
|
|
Actos Discussions Part 2: Dangers of the Drug
|
|
Links to higher heart disease rates have been associated with the use of Actos, and, in fact, Actos may cause as many heart problems as GlaxoSmithKline’s drug, Avandia. The American Heart Association reported that studies showed patients taking either diabetes drug were at least four times as likely to experience heart attacks, heart failure or even death.
|
|
Full Story
|
|
|
|
No article available
|
|
|
|
|
|